Faculty Information - Yutaka Osawa

（Last updated : 2025-05-20 14:05:28）

Yutaka Osawa
Department Kawasaki Medical School Kawasaki Medical School, Department of Neurology,

Position Associate Professor with Special Assignment

■ Journal

1.	2025/03	iPSC screening identifies CACNA2D2 as a potential therapeutic target for FTLD-Tau
2.	2023/05/01	Becker Muscular Dystrophy Accompanied by Anti-HMGCR Antibody-positive Immune-mediated Necrotizing Myopathy.
3.	2023/05	Circulating α-Klotho Counteracts Transforming Growth Factor-β-Induced Sarcopenia.
4.	2023/04	Alterations of ATG4A and LC3B in neurons derived from Alzheimer's disease patients.
5.	2023/02/10	Circulating α-Klotho Counteracts Transforming Growth Factor-β-Induced Sarcopenia
6.	2022/11	Caveolin 3 suppresses phosphorylation-dependent activation of sarcolemmal nNOS.
7.	2022/10	Maximal Multistage Shuttle Run Test-induced Myalgia in a Patient with Muscle Phosphorylase B Kinase Deficiency.
8.	2022/08/27	Caveolin 3 suppresses phosphorylation-dependent activation of sarcolemmal nNOS
9.	2022/04/15	Maximal Multistage Shuttle Run Test-induced Myalgia in a Patient with Muscle Phosphorylase B Kinase Deficiency
10.	2019/05	Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial.
11.	2018/01	Proteinuria in neuronal intranuclear inclusion disease
12.	2017/12	A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs)
13.	2017/10	Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
14.	2017/07	Slow-Myofiber Commitment by Semaphorin 3A Secreted from Myogenic Stem Cells.
15.	2016/10	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons.
16.	2015/02	Identification of the minimum Peptide from mouse myostatin prodomain for human myostatin inhibition.
17.	2015/01	A Second Pedigree with Amyloid-less Familial Alzheimer's Disease Harboring an Identical Mutation in the Amyloid Precursor Protein Gene (E693delta).
18.	2013/05	Local Applications of Myostatin-siRNA with Atelocollagen Increse Skeletal Muscle Mass and Recovery of Muscle Function
19.	2012/12	Taurine Ameliorates Impaired the Mitochondrial Function and Prevents Stroke-like Episodes in Patients with MELAS
20.	2012/10	Muscle-specific overexpression of caveolin 3 causes muscle atrophy, but not muscular dystrophy
21.	2012/08	An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy
22.	2011/05	Endoplasmic reticulum stress response in P104L mutant caveolin-3 transgenic mice
23.	2011/03	Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis
24.	2011/01	Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice
25.	2010/12	Rapid Screening for Japanese Dysferlinopathy by Fluorescent Primer Extension
26.	2010/08	The transthyretin gene is expressed in Schwann cells of peripheral nerves
27.	2010/04	Hereditary sensory ataxic neuropathy associated with proximal muscle weakness in the lower extremities
28.	2008/11	Caveolin-3 regulates myostatin signaling. Mini-review
29.	2008/08	Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
30.	2008/05	The transthyretin gene is expressed in human and rodent dorsal root ganglia.
31.	2006/11	Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
32.	2006/08	Bone marrow transplantation improves outcom in a mouse model of congenital muscular dystrophy.
33.	2006/08	Peripheral myelin protein 22 is expressed in human central nervous system.
34.	2005/08	Reduced amplitude of the sural nerve sensory action potential in PARK2 patients.
35.	2005	Is low SNAP amplitude in the sural nerve a useful diagnostic marker of PARK2 patient?
36.	2004/09	Skeletal muscle hyperplasia in the transgenic mice overexpressing the myostatin prodomain
37.	2004/01	Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity.
38.	2004	Restration of a myopathic phenotype of mutant caveolin-3 transgenic mice by crossing with mutant myostatin transgenic mice
39.	2003/10	Conduction block of varicella zoster virus neuropathy
40.	2001	Caveolin-3 and muscular dystrophy
Display 5 items
Display all(40)

■ Presentation

1.	2025/05/21	Myostatin inhibition restores sarcopenia and extends lifespan in the alpha-Klotho knockout mice （Speech，General）
2.	2024/10/09	Circulating alpha-Klotho combats TGF-beta-induced sarcopenia. （Poster notice，General）
3.	2024/10/09	Stapled inhibitory core peptide of myostatin alleviates dystrophic pathology in dystrophin-deficient DBA/2-mdx mice （Poster notice，General）
4.	2024/09/13	Caveolin 3 inhibits phosphorylation-dependent activation of sarcolemmal nNOS （Speech，General）
5.	2024/05/30	Circulating alpha-Klotho counteracts TGF-beta-induced sarcopeniaAlpha beta （Speech，Panelist at Symposium/Workshop (Appointed)）
6.	2023/06/02	Circulating alpha-Klotho combats TGF-beta-induced sarcopenia （Speech，General）
7.	2022/05/19	nNOS activation in the pathogenesis of caveolin-3-deficient limb-girdle muscular dystrophy 1C. （Poster notice，General）
8.	2022/05/18	A stapled myostatin inhibitory core peptide: its effect on caveolin-3- or dystrophin-deficient mice. （Speech，General）
9.	2021/05/22	Molecular crosstalk between caveolin 3 and nNOS: implications for Limb-girdle muscular dystrophy 1C （Speech，General）
10.	2021/05/21	Regulation of nNOS by Caveolin 3: Implications in the Pathogenesis Leading to LGMD1C. （Poster notice，General）
11.	2021/05/21	Therapeutic effects of an optimized myostatin inhibitory peptide. （Speech，General）
12.	2020/09/02	Caveolin 3 suppresses activation of sarcolemmal nNOS: implications in the pathogenesis of LGMD1C （Speech，General）
13.	2018/06/04	Taurine supplementation prevents stroke-like episodes in MELAS,the first-ever tRNA modification disorder （Poster notice，General）
14.	2017/11/05	The Effect of Myostatin Inhibition on Bone Loss in Murine Osteoporosis Models （Poster notice，General）
15.	2017/11/05	The effect of myostatin inhibition on bone loss in murine osteoporosis models. （Poster notice，General）
16.	2017/09/20	CAVEOLIN-3 CONTROLS SARCOLEMMAL nNOS ACTIVITY: IMPLICATION IN LIMB-GIRDLE MUSCULAR DYSTROPHY 1C （Poster notice，General）
17.	2017/09/19	The inhibitory core of myostatin prodomain: its suppression of ligand-receptor binding and potential for muscle wasting disorders. （Poster notice，General）
18.	2016/10	MELAS, a first-ever tRNA modification disorder is alleviated by taurine supplimentation therapy （Poster notice，General）
19.	2016/09/10	Hetreditary sensory ataxic neuropathy associated with proximal muscle weakness in the lower extremities: a new clinical entity? （Speech，General）
20.	2015/10/04	Taurine supplemental therapy in prevention of stroke-like episodes in MELAS
21.	2013/09/22	Taurine ameliorates mitochondrial dysfunction and prevents stroke-like episodes in patients with MELAS （Poster notice，General）
22.	2012/09/07	Regulation of caveolin-3 in myogenesis and muscular atrophy through type I TGF-beta receptor kinase. （Poster notice，General）
23.	2012/08/16	Caveolin-3 controls satellite cells and myoblasts through type I TGF-beta receptor kinase （Speech，General）
24.	2012/06/07	Roles of the caveolin-3-transforming gowth factor-beta axis in skeletal myogenesis and muscle atrophy. （Speech，General）
25.	2011/12/02	プロセシング酵素Furinの機能阻害とMyf5陽性筋細胞の動態（Speech）
26.	2011/11/19	Transthyretin gene expression in Schwann cells of peripheral nerves （Speech，General）
27.	2011/09/19	Sarcolemmal nNOS prevents muscular wasting in a caveolin-3-deficient limb-girdle muscular dystrophy 1C model （Speech，General）
28.	2011/09/18	Sarcolemmal nNOS prevents muscular wasting in a caveolin-3 deficient limb-girdle muscular dystrophy 1C model. （Speech，General）
29.	2011/09/18	Sarcolemmal nNOS prevents muscular wasting in a caveolin-3-deficient limb-girdle muscular dystrophy 1C model （Poster notice，General）
30.	2011/09/18	Wnt signalling acts as a switch controlling myoblast cell proliferation and differentiation （Poster notice，General）
31.	2010/10/14	Reprogrammed fibroblasts as a feasible source of cell-based therapy for muscular dystrophy （Poster notice，General）
32.	2010/10/13	A novel homozygous mutation of selenoprotein gene causes rigid spine syndorome with muscular dystrophy （Poster notice，General）
33.	2010/10	Reprogrammed fibroblasts as a feasible source of cell-based therapy for muscular dystrophy. （Speech，General）
34.	2010/07/21	Wound-healing MRL-MpJ phenotype improves outcome of dystrophin deficient mdx mice. （Speech，General）
35.	2010/07/18	Reprogrammed fibroblats are a source of cell therapy for caveolin-3-deficient and laminin α-2-deficient muscular dystrophies （Speech，General）
36.	2010/06/28	Transthyretin gene expression in dorsal root ganglia:where in it? （Speech）
37.	2009/09/11	Introduction of wound-healing MRL-MpJ phenotype improves skeletal muscle pathology in mdx mouse. （Poster notice，General）
38.	2009/09	Introduction of wound-healing MRL-MpJ phenotype improves skeletal muscle pathology in mdx mouse. （Speech，General）
39.	2009/07/04	Muscle mass regulation by myostatin-signaling related molecules （Speech，Panelist at Symposium/Workshop (Other)）
40.	2009/07/04	Myostatin blockade therapy for muscular dystrophy. （Speech，General）
41.	2008/10/01	A small-molecule inhibitor targeting transforming growth factor-b type Ⅰ receptor kinase ameliorate muscular atrophy in a mouse model of caveolin-3-deficient muscular dystrophy. （Speech，General）
42.	2007/10/17	Myostatin inhibition increases atrogin-1 expression and accelerates skeletal muscle atrophy under denervated conditions. （Poster notice，General）
43.	2007/07/14	Myostatin inhibition reverses satellite cell number in caveolin-3-deficient mouse muscle. （Poster notice，General）
44.	2007/07/14	Therapeutic effects of small-molecule inhibitors of type I TGF-b receptors for the treatment of muscular dystrophy. （Poster notice，General）
45.	2007/06/08	Inhibition of myostatin signaling through type I and type II myostatin receptors. （Speech，General）
46.	2006/10/04	Bone marrow transplantation improves outcome in a mouse model of congenital muscular dystrohy （Poster notice，General）
47.	2006/10/04	Molecular pathogenesis of caveolinopathy in a mouse model of LGMD1C （Speech，General）
48.	2006/10/04	MRL/MpJ wound-healing phenotype increases the myofiber size in mdx mouse skeletal muscle （Poster notice，General）
49.	2006/07/04	Myostatin inhibition can delay the onset of muscle weakness in a mouse model of amyotrophic lateral sclerosis. （Speech，General）
50.	2005/06/25	Dramatic reversal of muscular atrophy in caveolinopathy by myostatin blockade （Poster notice，General）
51.	2005/02/02	Is low SNAP amplitude in the sural nerve a useful diagnostic marker of PARK2 patient? （Poster notice，General）
52.	2004/10/04	Expression of Peripheral Myelin Protein 22 in Human Central Nervous System （Poster notice，General）
53.	2004/06/14	Reduced sural sensory nerve action potential (SNAP) amplitude as a possible diagnostic indicator of autosomal recessive juvenile parkinsonism （Poster notice，General）
54.	2003/09/03	Non-transcriptional activation of nitric oxide synthase induces hypertrophic cardiomyopathy with enhanced contractility in the P104L mutant caveolin-3 transgenic mice （Poster notice，General）
Display 5 items
Display all(54)